These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 32885740)

  • 1. Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an
    Khan RJ; Jha RK; Singh E; Jain M; Amera GM; Singh RP; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2022 Jan; 40(1):438-448. PubMed ID: 32885740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.
    Chandra A; Gurjar V; Qamar I; Singh N
    J Biomol Struct Dyn; 2021 Aug; 39(12):4201-4211. PubMed ID: 32462970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of potential inhibitors against SARS-CoV-2 endoribonuclease: RNA immunity sensing.
    Al-Rashedi NAM; Munahi MG; Ah ALObaidi L
    J Biomol Struct Dyn; 2022 Jul; 40(11):4879-4892. PubMed ID: 33357040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2'-O-ribose methyltransferase.
    Khan RJ; Jha RK; Amera GM; Jain M; Singh E; Pathak A; Singh RP; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2021 May; 39(8):2679-2692. PubMed ID: 32266873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoinformatics approach based identification of potential Nsp15 endoribonuclease modulators for SARS-CoV-2 inhibition.
    Savale RU; Bhowmick S; Osman SM; Alasmary FA; Almutairi TM; Abdullah DS; Patil PC; Islam MA
    Arch Biochem Biophys; 2021 Mar; 700():108771. PubMed ID: 33485847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of potential target endoribonuclease NSP15 inhibitors of SARS-COV-2 from natural products through high-throughput virtual screening and molecular dynamics simulation.
    Hu LC; Ding CH; Li HY; Li ZZ; Chen Y; Li LP; Li WZ; Liu WS
    J Food Biochem; 2022 May; 46(5):e14085. PubMed ID: 35128681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying the natural compound Catechin from tropical mangrove plants as a potential lead candidate against 3CL
    Jha RK; Khan RJ; Parthiban A; Singh E; Jain M; Amera GM; Singh RP; Ramachandran P; Ramachandran R; Sachithanandam V; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2022; 40(24):13392-13411. PubMed ID: 34644249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug designing against NSP15 of SARS-COV2 via high throughput computational screening and structural dynamics approach.
    Batool A; Bibi N; Amin F; Kamal MA
    Eur J Pharmacol; 2021 Feb; 892():173779. PubMed ID: 33275961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug repositioning to target NSP15 protein on SARS-CoV-2 as possible COVID-19 treatment.
    Sixto-López Y; Martínez-Archundia M
    J Comput Chem; 2021 May; 42(13):897-907. PubMed ID: 33713492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of nonstructural protein 15 of SARS-CoV-2 by golden spice: A computational insight.
    Singh R; Bhardwaj VK; Purohit R
    Cell Biochem Funct; 2022 Dec; 40(8):926-934. PubMed ID: 36203381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study.
    Vijayan V; Pant P; Vikram N; Kaur P; Singh TP; Sharma S; Sharma P
    J Biomol Struct Dyn; 2021 Oct; 39(17):6713-6727. PubMed ID: 32741322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
    Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
    J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated docking and enhanced sampling-based selection of repurposing drugs for SARS-CoV-2 by targeting host dependent factors.
    Kumawat A; Namsani S; Pramanik D; Roy S; Singh JK
    J Biomol Struct Dyn; 2022; 40(20):9897-9908. PubMed ID: 34155961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D is a potential inhibitor of COVID-19: In silico molecular docking to the binding site of SARS-CoV-2 endoribonuclease Nsp15.
    Shalayel MH; Al-Mazaideh GM; Aladaileh SH; Al-Swailmi FK; Al-Thiabat MG
    Pak J Pharm Sci; 2020 Sep; 33(5):2179-2186. PubMed ID: 33824127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.
    de Oliveira OV; Rocha GB; Paluch AS; Costa LT
    J Biomol Struct Dyn; 2021 Jul; 39(11):3924-3933. PubMed ID: 32448085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reporting dinaciclib and theodrenaline as a multitargeted inhibitor against SARS-CoV-2: an
    Ahmad S; Pasha Km M; Raza K; Rafeeq MM; Habib AH; Eswaran M; Yadav MK
    J Biomol Struct Dyn; 2023 Jun; 41(9):4013-4023. PubMed ID: 35451934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing immune boosting and anti-viral efficacy of
    Dinata R; Nisa N; Arati C; Rasmita B; Uditraj C; Siddhartha R; Bhanushree B; Saeed-Ahmed L; Manikandan B; Bidanchi RM; Abinash G; Pori B; Khushboo M; Roy VK; Gurusubramanian G
    J Biomol Struct Dyn; 2024; 42(1):43-81. PubMed ID: 37021347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target.
    Arun KG; Sharanya CS; Abhithaj J; Francis D; Sadasivan C
    J Biomol Struct Dyn; 2021 Aug; 39(13):4647-4658. PubMed ID: 32571168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the dual effects of antiviral drugs on SARS-CoV-2 receptors and the ACE2 receptor using structure-based virtual screening and molecular dynamics simulation.
    Jahantigh HR; Ahmadi N; Shahbazi B; Lovreglio P; Habibi M; Stufano A; Gouklani H; Ahmadi K
    J Biomol Struct Dyn; 2023; 41(13):6051-6073. PubMed ID: 35876061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.